tetano
Editor, Senior Moderator
Clin Infect Dis
. 2023 Mar 2;ciad084.
doi: 10.1093/cid/ciad084. Online ahead of print.
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Alexandra N Lea[SUP] 1 [/SUP], Wendy A Leyden[SUP] 1 [/SUP], Oleg Sofrygin[SUP] 1 [/SUP], Ben J Marafino[SUP] 1 [/SUP], Jacek Skarbinski[SUP] 1 2 [/SUP], Sonia Napravnik[SUP] 3 [/SUP], Deana Agil[SUP] 3 [/SUP], Michael Augenbraun[SUP] 4 [/SUP], Lorie Benning[SUP] 5 [/SUP], Michael A Horberg[SUP] 6 [/SUP], Celeena Jefferson[SUP] 6 [/SUP], Vincent C Marconi[SUP] 7 [/SUP], Lesley S Park[SUP] 8 [/SUP], Kirsha S Gordon[SUP] 9 10 [/SUP], Lisa Bastarache[SUP] 11 [/SUP], Srushti Gangireddy[SUP] 11 [/SUP], Keri N Althoff[SUP] 5 [/SUP], Sally B Coburn[SUP] 5 [/SUP], Kelly A Gebo[SUP] 12 [/SUP], Raynell Lang[SUP] 13 [/SUP], Carolyn Williams[SUP] 14 [/SUP], Michael J Silverberg[SUP] 1 [/SUP]
Affiliations
Abstract
Background: People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection.
Methods: Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only).
Results: Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20-1.44]), COVID-19 hospitalizations (1.29 [1.15-1.45]), and mechanical ventilation or death (1.51 [1.19-1.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval, .73-.99]) and PWoH (0.71 [.62-.81]).
Conclusions: Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.
Keywords: COVID-19; HIV; SARS-CoV-2; hospitalization; tenofovir.
. 2023 Mar 2;ciad084.
doi: 10.1093/cid/ciad084. Online ahead of print.
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Alexandra N Lea[SUP] 1 [/SUP], Wendy A Leyden[SUP] 1 [/SUP], Oleg Sofrygin[SUP] 1 [/SUP], Ben J Marafino[SUP] 1 [/SUP], Jacek Skarbinski[SUP] 1 2 [/SUP], Sonia Napravnik[SUP] 3 [/SUP], Deana Agil[SUP] 3 [/SUP], Michael Augenbraun[SUP] 4 [/SUP], Lorie Benning[SUP] 5 [/SUP], Michael A Horberg[SUP] 6 [/SUP], Celeena Jefferson[SUP] 6 [/SUP], Vincent C Marconi[SUP] 7 [/SUP], Lesley S Park[SUP] 8 [/SUP], Kirsha S Gordon[SUP] 9 10 [/SUP], Lisa Bastarache[SUP] 11 [/SUP], Srushti Gangireddy[SUP] 11 [/SUP], Keri N Althoff[SUP] 5 [/SUP], Sally B Coburn[SUP] 5 [/SUP], Kelly A Gebo[SUP] 12 [/SUP], Raynell Lang[SUP] 13 [/SUP], Carolyn Williams[SUP] 14 [/SUP], Michael J Silverberg[SUP] 1 [/SUP]
Affiliations
- PMID: 36861341
- DOI: 10.1093/cid/ciad084
Abstract
Background: People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection.
Methods: Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only).
Results: Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20-1.44]), COVID-19 hospitalizations (1.29 [1.15-1.45]), and mechanical ventilation or death (1.51 [1.19-1.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval, .73-.99]) and PWoH (0.71 [.62-.81]).
Conclusions: Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.
Keywords: COVID-19; HIV; SARS-CoV-2; hospitalization; tenofovir.